1-4 ChangeControl
1-4 ChangeControl
1-4 ChangeControl
Luisa Stoppa
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors Nanjing, the Peoples Republic of China 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 2 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Programme
To introduce the general elements on change control
To train you in the guidelines (WHO-GMP, PIC/S guidelines, EU-GMP)
To become confident with SOP, forms and records of Change Control System To develop your inspection plan on change control
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 3 | Nanjing, the Peoples Republic of China, 16-20 November 2009
However, the GMP guideline basically contains only few notes about the handling of changes
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 7 | Nanjing, the Peoples Republic of China, 16-20 November 2009
As the change control is considered an essential element of the pharmaceutical quality assurance system, it is logical the person responsible is quality assurance (QA representative, QA head)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 8 | Nanjing, the Peoples Republic of China, 16-20 November 2009
The change control monitors all types of changes which can influence the process or product quality and states the measures necessary for implementing the change or decides that a change should not be implemented
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 9 | Nanjing, the Peoples Republic of China, 16-20 November 2009
QM statement standard operating procedure / instructions records / forms and other relevant documents
change policy operating instruction for change control change requests and other relevant documents
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 10 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 11 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 12 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 13 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 14 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 15 | Nanjing, the Peoples Republic of China, 16-20 November 2009
EU-GMP
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 16 | Nanjing, the Peoples Republic of China, 16-20 November 2009
examples
Replacement of apparatus part of the same design Change of cleaning agent for floors
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 17 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 18 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 19 | Nanjing, the Peoples Republic of China, 16-20 November 2009
WHO-GMP
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 20 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 21 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 22 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 23 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 24 | Nanjing, the Peoples Republic of China, 16-20 November 2009
With trials, there is a risk that these intended temporary changes gradually become permanent changes without a formal change control procedure being carried out How long a trial is retained and whether it is withdrawn after a trial phase or be introduce permanently, should be included in the same procedure change control as all other changes
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 25 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Notification - description of deviation Evaluation - effect on product quality - definition of corrective actions - effect on validation status - definition of revalidation measures Implementation of deviation Closing
- effect on validation status - definition of revalidation measures Approval Implementation of change Closing
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 27 | Nanjing, the Peoples Republic of China, 16-20 November 2009
PIC/S guideline
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 29 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 30 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 31 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 32 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 33 | Nanjing, the Peoples Republic of China, 16-20 November 2009
EU-GMP
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 34 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control requires a written procedure to establish at least the following steps:
What type of changes does change control take into account? What are the requirements for urgent changes? For which areas does this operating procedure apply? Who can suggest changes? How are changes requested (forms, method of communication)? How are changes graded and who is responsible for the rating? How are the measures for carrying out the change established? Who is responsible for the implementation and monitoring of all measures? Who is included in the change control team? What are the duties of the change control team? How is the change documented (format, content, storage)? Who is responsible to authorize changes?
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 35 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control requires a written procedure to establish at least the following steps:
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 36 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control requires a written procedure to establish at least the following steps:
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 37 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
All quality-relevant changes should be documented
All actions to be taken, including the need for and extent of qualification or validation, should be described
The records can be archived in paper form or electronically When storing documents, raw data and other relevant documents for change should be kept accessible
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 38 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Changes requiring control are generally documented in the form of a change request in which the applicant for the change proposes the type of change, suggests the timeframes and measures for carrying out the change
The change control team authorizes or not the change The documentation for the change procedure should show that the change was evaluated (risk analysis)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 39 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
WHO-GMP
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 40 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure (example 1)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 41 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure (example 2, 1/2)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 42 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure (example 2, 2/2)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 43 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure includes flow chart of the change control process and the change request form (or change form)
Change request form records a request for change so that each change is documented before it is approved The change request form includes the description of the change, the benefits, costs, urgency of the change, change impact
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 44 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure: flow chart (example 1)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 45 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure: flow chart (example 2)
More information required
Change Request Submission Evaluation of Change Impact Validation Change Request Change Activities
Change Activities
Approval Activities Completion Change Closed Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 46 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure: flow chart (example 3)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 47 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure: flow chart (example 4)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 48 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control procedure: flow chart for change master documents (example 1)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 49 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change request form (example 1, 1/2)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 50 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change request form (example 1, 2/2)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 51 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change request form (example 2, 1/2)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 52 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change request form (example 2, 2/2)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 53 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change request form (example 3)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 54 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change database: electronic copy
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 55 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Documentation
Change control logbook
Page:__ of ____
Examples of changes
Changes to the cleaning procedure
- use of a new cleaning agent - change in concentration / volumes of cleaning agent - change in volumes of rinsing water - change of cleaning process parameters
Examples of changes
Changes to the product - changes to composition (reformulation with different excipients)
- changes to the manufacturing process (i.e. transfer of a product)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 58 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Inspection plan
To ask for the Change Control standard operating procedure
To check that all relevant steps for change control implementation are detailed To choose some applications (from the list in the logbook)
To verify the applications and all requested documents (change request form, investigation, request and closing date)
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 59 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Conclusion
The old adage says: the only thing constant is change!
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 60 | Nanjing, the Peoples Republic of China, 16-20 November 2009
Reference documents
WHO GMP guidelines Technical Report series n. 937
EU GMP guidelines, Part I annex 15 ICH Q7A or EU GMP Part II chapter 13 PIC/S Recommendations PI 006-3
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors 61 | Nanjing, the Peoples Republic of China, 16-20 November 2009
[email protected]
Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009
62 |